Market open
Ovid Therapeutics/$OVID
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ovid Therapeutics
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
Ticker
$OVID
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
40
Website
OVID Metrics
BasicAdvanced
$92M
Market cap
-
P/E ratio
-$0.42
EPS
0.43
Beta
-
Dividend rate
Price and volume
Market cap
$92M
Beta
0.43
52-week high
$4.10
52-week low
$0.68
Average daily volume
120K
Financial strength
Current ratio
5.729
Quick ratio
5.452
Long term debt to equity
15.859
Total debt to equity
17.311
Management effectiveness
Return on assets (TTM)
-32.61%
Return on equity (TTM)
-29.81%
Valuation
Price to revenue (TTM)
161.994
Price to book
1.04
Price to tangible book (TTM)
1.04
Price to free cash flow (TTM)
-1.732
Growth
Revenue change (TTM)
186.16%
Earnings per share change (TTM)
-39.92%
3-year revenue growth (CAGR)
-86.31%
3-year earnings per share growth (CAGR)
-38.45%
What the Analysts think about OVID
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ovid Therapeutics stock.
OVID Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
OVID Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
OVID News
AllArticlesVideos
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
GlobeNewsWire·2 months ago
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
Accesswire·3 months ago
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
Accesswire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ovid Therapeutics stock?
Ovid Therapeutics (OVID) has a market cap of $92M as of November 08, 2024.
What is the P/E ratio for Ovid Therapeutics stock?
The price to earnings (P/E) ratio for Ovid Therapeutics (OVID) stock is 0 as of November 08, 2024.
Does Ovid Therapeutics stock pay dividends?
No, Ovid Therapeutics (OVID) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Ovid Therapeutics dividend payment date?
Ovid Therapeutics (OVID) stock does not pay dividends to its shareholders.
What is the beta indicator for Ovid Therapeutics?
Ovid Therapeutics (OVID) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.